Brilinta OK'd for Primary Prevention

]]>(MedPage Today) -- Ticagrelor (Brilinta) gained an indication expansion to reduce risk of a first heart attack or stroke in high-risk patients with coronary artery disease, AstraZeneca announced.FDA approval centered on the phase III THEMIS trial...